Meta‐analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder
- 23 October 2018
- journal article
- review article
- Published by Wiley in Neurourology and Urodynamics
- Vol. 38 (1) , 22-30
Abstract
Aim: We conducted a meta‐analysis to evaluate the safety and efficacy of mirabegron (50 mg) and solifenacin (5 mg) monotherapy for overactive bladder (OAB) during a 12‐week cycle.Methods: Randomized controlled trials (RCTs) of mirabegron and solifenacin for OAB were searched systematically by using MEDLINE, EMBASE, and the Cochrane Controlled Trials Register. The reference lists of retrieved studies were also perused.Results: Five RCTs which compared solifenacin with mirabegron were studied. Mirabegron achieved the same effect as solifenacin in treating OAB. The mean number of incontinence episodes per 24 h (P = 0.20), mean number of micturitions per 24 h (P = 0.11), mean number of urgency episodes per 24 h (P = 0.23), and mean volume voided per micturition (P = 0.05) suggested that mirabegron and solifenacin had no significant differences in terms of OAB treatment. With regard to drug‐related treatment‐emergent adverse events (DR‐TEAEs) and dry mouth, mirabegron showed better tolerance than solifenacin. Post‐voiding residual volume showed a distinct difference in the two groups. Hypertension and tachycardia did not show a significant difference between the two groups, but the pulse rate did.Conclusion: The therapeutic effect of mirabegron is similar to that of solifenacin, and mirabegron does not increase the risk of adverse events (AEs).Keywords
This publication has 29 references indexed in Scilit:
- Re: Persistence with Prescribed Antimuscarinic Therapy for Overactive Bladder: A UK ExperienceJournal of Urology, 2013
- Re: Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European-Australian Phase 3 TrialJournal of Urology, 2013
- Re: Effect of Bothersome Overactive Bladder Symptoms on Health-Related Quality of Life, Anxiety, Depression, and Treatment Seeking in the United States: Results from EpiLUTSJournal of Urology, 2013
- The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) studyBJU International, 2009
- The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-AnalysisEuropean Urology, 2008
- Urodynamic parameters after solifenacin treatment in men with overactive bladder symptoms and detrusor underactivityNeurourology and Urodynamics, 2008
- Acetylcholine and Molecular Components of its Synthesis and Release Machinery in the UrotheliumEuropean Urology, 2007
- Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant miceNature Neuroscience, 2002
- Current pharmacotherapeutic strategies for overactive bladderExpert Opinion on Pharmacotherapy, 2002
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986